BHIVA Audit 2021: hepatitis C and HIV co-infection

Welcome to the 2021 BHIVA national audit of hepatitis C and HIV co-infection. This comprises two elements:

- A brief survey of clinic arrangements for managing co-infected individuals - this should be completed once for each HIV specialist care service
- A case-note review of adults (age 16 or over) living with HIV who are currently RNA-positive and infected with hepatitis C (HCV). Please complete the case-note review for all such individuals under the care of your HIV service, or the 40 most recent attenders if there are more than 40 in total.

If you make a mistake or wish to change an earlier answer, please do not use your browser "Back" button. Instead use the "Previous" button at the bottom of each questionnaire page.

Please direct any queries to BHIVA’s clinical audit co-ordinator Hilary Curtis, hilary@regordane.net (mailto: hilary@regordane.net?subject=BHIVA%20audit%20query)

There are 46 questions in this survey.

Select questionnaire

The token/site-code you entered is for the following clinic or department:

{TOKEN:ATTRIBUTE_1}
{TOKEN:ATTRIBUTE_2}
{TOKEN:ATTRIBUTE_3}

Please choose all that apply:

☐ Please tick to confirm this is the correct clinic/department

The questionnaire will appear if the box is ticked. If yours is not the department/clinic named above, then please consult your service's lead for HIV clinical audit to request the correct token/site-code. If s/he is not able to provide this, then please contact BHIVA's clinical audit co-ordinator, Hilary Curtis, hilary@regordane.net (mailto: hilary@regordane.net?subject=BHIVA%20site-code%20query) 07984 239556.

If the department/clinic above is correct except for minor details, eg a change of name, then please tick the box to proceed.
Which questionnaire do you wish to complete? *

Only answer this question if the following conditions are met:
Answer was at question '1 [TokenCheck]' (The token/site-code you entered is for the following clinic or department: {TOKEN:ATTRIBUTE_1} {TOKEN:ATTRIBUTE_2} {TOKEN:ATTRIBUTE_3} )

Please choose only one of the following:

- Brief survey of clinic arrangements for management of hepatitis/HIV co-infection
- Case-note review of individuals RNA-positive for hepatitis C and infected with HIV

Characteristics of audited individual

What was the result of this individual's most recent test for hepatitis C RNA? *

Please choose only one of the following:

- Detectable
- Not detectable
- Not recorded

This question requires an answer.

Only answer this question if the following conditions are met:
Answer was 'Not detectable' or 'Not recorded' at question '3 [Eligibility]' (What was the result of this individual's most recent test for hepatitis C RNA?)

This individual is not eligible for inclusion in the audit. Only adults (16 or over) living with HIV and RNA-positive for hepatitis C are eligible.

Current gender:

Only answer this question if the following conditions are met:
Eligible for audit

Please choose only one of the following:

- Male (including trans)
- Female (including trans)
- Non-binary or other
- Declined to say
Does individual identify as trans?

Only answer this question if the following conditions are met:
Eligible for audit

Please choose only one of the following:

- Yes
- No
- Not recorded

Age in years:

Only answer this question if the following conditions are met:
Eligible for audit

Please write your answer here:

Exposure factors by which this individual may have acquired HIV and blood-borne infections (tick ALL that apply):

Only answer this question if the following conditions are met:
Eligible for audit

Please choose all that apply:

- MSM
- Heterosexual sex
- Injecting non-chemsex drugs
- Injecting chemsex drugs
- Blood or blood products
- Not known

Other, please state::


Behaviours in which this individual currently engages (tick ALL that apply):

Only answer this question if the following conditions are met:
Eligible for audit

Please choose all that apply:

- [ ] MSM
- [ ] Heterosexual sex
- [ ] Injecting non-chemsex drugs
- [ ] Injecting chemsex drugs
- [ ] Non-injecting use of chemsex drugs

Most recent serology for hepatitis B:

Only answer this question if the following conditions are met:
Eligible for audit

Please choose the appropriate response for each item:

<table>
<thead>
<tr>
<th></th>
<th>Positive</th>
<th>Negative</th>
<th>Not recorded</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hepatitis B core antibody (anti-HBc)</strong></td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td><strong>Hepatitis B surface antibody (anti-HBs) - &quot;positive&quot; means 10 mIU or above</strong></td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
<tr>
<td><strong>Hepatitis B surface antigen (HBsAg)</strong></td>
<td>[ ]</td>
<td>[ ]</td>
<td>[ ]</td>
</tr>
</tbody>
</table>

When was the anti-HBs titre last measured?

Only answer this question if the following conditions are met:
anti-HBs positive, HBsAg negative, and anti-HBc negative or not recorded

Please choose only one of the following:

- [ ] Within last 18 months
- [ ] 18 months to 3 years
- [ ] Not recorded as done within last 3 years
Please tick if this individual:
Only answer this question if the following conditions are met:
Negative for anti-HBc, anti-HBs and HBsAg
Please choose only one of the following:

- [ ] Was previously hepatitis B core antibody (anti-HBc) positive but has lost antibody
- [ ] Is a known poor responder to hepatitis B vaccination

Hepatitis B DNA status:
Only answer this question if the following conditions are met:
HBsAg positive
Please choose only one of the following:

- [ ] Detectable, greater than 2000 IU/ml
- [ ] Detectable, lower than 2000 IU/ml
- [ ] Not detectable
- [ ] Not recorded

Management of hepatitis C infection

What is the HCV genotype, if known?
Please choose only one of the following:

- [ ] 1
- [ ] 2
- [ ] 3
- [ ] 4
- [ ] 5
- [ ] 6
- [ ] Not known or not recorded
Has this individual received treatment for hepatitis C infection?

Please choose only one of the following:

- No - this individual has not been treated for hepatitis C
- Yes - has been or is currently being treated
- Not recorded whether treated

Answer "Yes" if a course of treatment was started but not completed.

When was the individual (last) treated for hepatitis C?

Only answer this question if the following conditions are met:
Treated for HCV

Please choose only one of the following:

- Treatment is currently in progress
- Most recent course of treatment started during 2018-21
- Most recent course started during 2015-17
- Most recent course started during 2014 or earlier
- Not recorded

If treated more than once, answer for the most recent course of treatment.
What was the regimen for the current or most recent course of treatment?

Only answer this question if the following conditions are met:
Most recent treatment started 2018 or later
Please choose only one of the following:

- Elbasvir/Grazoprevir (Zepatier)
- Glecaprevir/Pibrentasvir (Maviret)
- Sofosbuvir/Velpatasvir (Epclusa) without Ribavirin (Copegus)
- Sofosbuvir/Velpatasvir (Epclusa) with Ribavirin (Copegus)
- Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi)
- Sofosbuvir/Ledipasvir (Harvoni) with or without Ribavirin (Copegus)
- Ombitasvir/Paritaprevir/RTV (Viekirax) with Ribavirin (Copegus)
- Ombitasvir/Paritaprevir/RTV (Viekirax) + Dasabuvir (Exviera) with or without Ribavirin (Copegus)
- Sofosbuvir (Sovaldi) + Daclatasvir (Daklinza) with or without Ribavirin (Copegus)
- Not recorded

Other, please state: 

Was the current or most recent course of treatment provided through participation in a clinical trial?

Only answer this question if the following conditions are met:
Most recent treatment started 2018 or later
Please choose only one of the following:

- Yes
- No
- Not recorded
Did this individual need to modify ARVs to avoid interactions with drugs used in the current or most recent course of hepatitis C treatment?

Only answer this question if the following conditions are met:
Most recent treatment started 2018 or later

Please choose only one of the following:

- Yes
- No
- Not sure

Why does this individual have detectable HCV RNA despite having received treatment?

Only answer this question if the following conditions are met:
Treated

Please choose only one of the following:

- Re-infected after previous successful treatment
- The (most recent) course of treatment was completed but did not achieve sustained virological response (SVR)
- The (most recent) course of treatment was not completed and did not achieve SVR
- Other reason(s), please state:  

Is re-treatment planned?

Only answer this question if the following conditions are met:
Re-infected after previous treatment

Please choose only one of the following:

- Re-infection is recent, waiting for possible spontaneous clearance before considering re-treatment
- Re-treatment is currently planned
- In accordance with clinic policy, re-treatment is not currently planned
- Individual does not wish to be re-treated
- Other, please comment:  

Why has this individual not received treatment for hepatitis C infection? Please tick all that apply and expand your answer(s) with comments if you wish - we would like to understand the reasons as fully as possible.

Only answer this question if the following conditions are met:
Not treated

Please choose all that apply and provide a comment:

- Recently acquired hepatitis C infection (within last 6 months) which may clear spontaneously
- Treatment is currently planned
- Individual does not believe treatment is effective
- Individual believes treatment would be toxic
- Individual does not wish to be treated - please add reasons, if known
- Individual is considered unlikely to adhere well to treatment
- Individual is likely to be at significant risk of re-infection following treatment
- Individual is not engaging in care
- Individual is not contactable - eg no phone

Other: 

[ ]
Is it documented that:
Please choose the appropriate response for each item:

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Not sure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individual has received counselling regarding hepatitis C transmission risk factors and safe sex?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Individual has been offered harm reduction support (or this is recorded as not necessary)?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partner notification has been conducted (or recorded as not necessary) for hepatitis C as well as HIV?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

When was the last recorded enquiry/discussion about alcohol use?
Please choose only one of the following:

- Within past 9 months
- 9-18 months ago
- 18 months to 3 years ago
- Longer, or none recorded

When was fibrosis last assessed?
Please choose only one of the following:

- Within past 18 months
- Done but more than 18 months ago
- Not done
- Not recorded
Method(s) used at most recent assessment:
Only answer this question if the following conditions are met:
Fibrosis assessment has been done
Please choose all that apply:

- Liver biopsy
- Elastography (eg Fibroscan)
- Blood markers (eg FIB4)
- Not recorded

Fibrosis stage:
Only answer this question if the following conditions are met:
Fibrosis assessment has been done
Please choose only one of the following:

- Normal
- Minimal or mild fibrosis
- Moderate fibrosis
- Severe fibrosis/cirrhosis
- Not recorded

Management of liver disease

Please select the option that best describes arrangements for clinical management of this individual:
Please choose only one of the following:

- An HIV specialist and a specialist hepatologist share care through an agreed care plan
- An HIV specialist and a specialist hepatologist share care, but without an agreed plan
- An HIV specialist with an interest in hepatitis provides care
- Other, please describe:
How is information shared between the HIV and hepatology specialists?

Only answer this question if the following conditions are met:
Care is shared between HIV specialist and specialist hepatologist

Please choose only one of the following:

- Both specialists record information in the same patient record (eg within one trust)
- Communication is via letter/email or similar
- Other, please describe: ___________________________

Select the first answer that applies.

When was the most recent letter/email/similar from the hepatologist to the HIV specialist?

Only answer this question if the following conditions are met:
Communication is via letter/email etc

Please choose only one of the following:

- Within last 6 months
- 6-12 months ago
- 12-18 months ago
- Longer, or none recorded

Is it documented that the individual has either been vaccinated against hepatitis A or is naturally immune (IgG positive)?

Please choose only one of the following:

- Yes
- No
- Not sure
When was liver ultrasound last performed?

Only answer this question if the following conditions are met:
Individual has moderate or severe fibrosis or cirrhosis

Please choose only one of the following:

- Within past 9 months
- 9-18 months ago
- Done but more than 18 months ago
- Not recorded as done
- Not known

When was alpha-fetoprotein last measured?

Only answer this question if the following conditions are met:
Individual has moderate or severe fibrosis or cirrhosis

Please choose only one of the following:

- Within past 9 months
- 9-18 months ago
- Done but more than 18 months ago
- Not recorded as done
- Not known

Has the individual been diagnosed with hepatoma?

Only answer this question if the following conditions are met:
Individual has moderate or severe fibrosis or cirrhosis

Please choose only one of the following:

- Yes
- No
- Not sure
Has upper GI endoscopy been performed?
Only answer this question if the following conditions are met:
Individual has severe fibrosis/cirrhosis
Please choose only one of the following:
- Yes
- No
- Not sure

Have signs of decompensation occurred (ie encephalopathy, ascites and/or variceal haemorrhage)?
Only answer this question if the following conditions are met:
Individual has severe fibrosis/cirrhosis
Please choose only one of the following:
- Yes
- No
- Not sure

Clinic survey: management of HIV/hepatitis C co-infection

What are the estimated numbers of people with HIV:
Please write your answer(s) here:
Who accessed HIV care via your service/clinic within the last year?
[ ]
Of these, who are antibody positive for hepatitis C?
[ ]
Of these, who are currently infected with hepatitis C (i.e. with detectable RNA)?
[ ]
Of these, who are approved for or currently receiving hepatitis C treatment?
[ ]
Which of the following best describes your service's arrangements for management of hepatitis B/C in individuals with HIV?

Please choose only one of the following:

- Our service is a regional specialist or referral centre for HIV/hepatitis co-infection
- Managed via a co-infection clinic within the HIV service (complex cases may be referred)
- Referred to local hepatology service
- Referred to regional specialist co-infection clinic
- Other, please describe:

Is there a regular joint clinic led by specialists in both HIV and hepatology?

Only answer this question if the following conditions are met:
Co-infected individuals are managed within the HIV service

Please choose only one of the following:

- Yes
- No
- Not sure

Which of the following best describes current access to repeat hepatitis C treatment for individuals who become re-infected following previous successful treatment?

Please choose only one of the following:

- Confident that re-treatment would be offered in most cases
- Re-treatment might be offered in some cases depending on individual circumstances
- Re-treatment would not ordinarily be offered
- Not sure
Does your clinic system allow you to accurately update HARS if an individual’s hepatitis C status changes from infected to uninfected (ie clearance)?

Please choose only one of the following:

- Yes
- No
- Not sure
- Not applicable - outside England and not using HARS

Does your service routinely conduct partner notification for hepatitis C?

Please choose only one of the following:

- Yes, we do this for both hepatitis C and HIV
- We do this routinely for HIV but not for hepatitis C
- Partner notification is done elsewhere for both HIV and hepatitis C
- Not sure

Is there provision locally for?

Please choose the appropriate response for each item:

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Not sure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peer support for hepatitis C (not just for HIV)?</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Home/community visits to encourage care engagement for people with hepatitis C?</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
Please describe any specific measures your service has taken to encourage uptake of hepatitis C treatment among people co-infected with HIV:

Please write your answer here:

If you wish to comment specifically on how the covid-19 pandemic has affected management of hepatitis co-infection for your HIV patients, then please do so here:

Please write your answer here:

Submit

When you are satisfied with your response, please click the "Submit" button - your answers are not saved until you do so.

Thank you. Your answers have been saved. If you would like a copy for your own records, to print or save as a pdf, then please right-click on "Print your answers" now to open the completed questionnaire in a new tab or window, before clicking any other link.

Otherwise:

- Please click here if you wish to return to the start to enter data for a different patient or complete the clinic survey (https://surveys.bhiva.org/index.php/survey/index/sid/131697/newtest/Y/lang/en/token/{TOKEN:TOKEN})
- Or please click here to go to the BHIVA website. (https://www.bhiva.org/)

Submit your survey.
Thank you for completing this survey.